JOIN US FOR A FREE VIRTUAL FORUM:

Early Intervention In Schizophrenia: Targeting Metabolic Dysfunction

TUESDAY NOVEMBER 7, 2017
12PM ET | 9AM PT

Increasingly, schizophrenia is considered a medical psychiatric disease. There is evidence that metabolic changes occur within the first episode of psychosis, and within the first few weeks of initiating antipsychotic treatment. Presently, there are treatment options available that can address these dangers, and they need to be implemented as early as possible in the course of schizophrenia. Early Intervention (EI) programs are aimed at early detection of the disease, prevention of conversion to manifested psychosis, and phase-specific treatment to reduce the development of chronic disabilities. Please join Christoph Correll, MD, and John Newcomer, MD, as they revisit the various strategies for EI in psychotic syndromes while focusing on strategies to intervene early in the process to improve metabolic risk.

Speakers are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. and will be compensated for participation in this event.

Featuring:

Christoph Correll, MD
Christoph Correll, MD, is a Professor of Psychiatry at Hofstra Northwell School of Medicine and Medical Director of the Recognition & Prevention (RAP) Program at Zucker Hillside Hospital.

Dr. Correll completed his medical studies at the Free University of Berlin in Berlin, Germany, and the Dundee University Medical School in Dundee, Scotland. Both his general psychiatry and child and adolescent psychiatry fellowships were completed at the Zucker Hillside Hospital in New York.

John Newcomer, MD
John Newcomer, MD, is a Professor of Integrated Medical Science at the Charles E. Schmidt College of Medicine at Florida Atlantic University (FAU). He has served as a Principal Investigator on research grants funded through the National Institutes of Health (NIH) for over 20 years, and has held a series of research leadership positions at Washington University in St. Louis, the University of Miami, and FAU. He also served as Vice Dean for Research & Innovation at FAU.

Dr. Newcomer received his medical degree from Wayne State University School of Medicine in Detroit, Michigan. He completed his residency and research fellowship in psychiatry at Stanford University School of Medicine.

Carolyn Tyler, PhD, Senior Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc., will be the moderator of this event.

Additional Resources On PsychU:

Health Technology Intervention After Hospitalization For Schizophrenia: Service Utilization & User Satisfaction Research Summary

- Why Schizophrenia Remains 'Top Of Mind' At Health Plans
- Recovery In Schizophrenia: What Consumers Know & Do Not Know

REGISTER & ACCESS THESE RESOURCES TODAY AT: www.PsychU.org